Non-invasive tests for fibrotic MASH: Decision aids in MASH therapeutics and predictors of liver-related events.

The approval of resmetirom and semaglutide for fibrotic MASH has created an urgent need for tools that will aid identify candidates for drug therapy and assess response non-invasively. Existing NITs often misclassify patients with fibrotic MASH. Novel NITs may change the paradigm of MASLD management, but they need to be cost-effective, widely available, and reproducible to reach clinical practice.